Genome-scale mutational signatures of aflatoxin in cells, mice, and human tumors

Genome Research

Volumn 27, Issue 9, 2017, Pages 1475-1486

  Huang, Mi Ni ^a   Yu, Willie ^a   Teoh, Wei Wei ^b   Ardin, Maude ^c   Jusakul, Apinya ^a,b   Ng, Alvin Wei Tian ^a,d   Boot, Arnoud ^a   Abedi Ardekani, Behnoush ^c   Villar, Stephanie ^c   Myint, Swe Swe ^b   Othman, Rashidah ^b   Poon, Song Ling ^a,b   Heguy, Adriana ^e   Olivier, Magali ^c   Hollstein, Monica ^c   Tan, Patrick ^a   Teh, Bin Tean ^a,b   Sabapathy, Kanaga ^a,b   Zavadil, Jiri ^c   Rozen, Steven G ^a  

^a DUKE NUS MEDICAL SCHOOL   (Singapore)

^b DIVISION OF MEDICAL ONCOLOGY   (Singapore)

^c INTERNATIONAL AGENCY FOR RESEARCH ON CANCER   (France)

^d NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^e NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AFLATOXIN; DINUCLEOTIDE; DNA; GUANINE; HEPATITIS B SURFACE ANTIGEN; MESSENGER RNA; TRINUCLEOTIDE; AFLATOXIN B1; CARCINOGEN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER GENETICS; CONTROLLED STUDY; DECOMPOSITION; DNA REPAIR; DNA REPLICATION TIMING; EXOME; GENE MUTATION; GENE SEQUENCE; GENETIC VARIABILITY; HEPATITIS B; HUMAN; HUMAN CELL; HUMAN GENOME; LIVER CELL; LIVER CELL CARCINOMA; MOUSE; MUTATIONAL SIGNATURE; NONHUMAN; PRIORITY JOURNAL; SOMATIC MUTATION; TRANSGENE; WHOLE EXOME SEQUENCING; ANIMAL; CHEMICALLY INDUCED; CHINA; DNA MUTATIONAL ANALYSIS; DRUG EFFECTS; GENETICS; LIVER TUMOR; MUTATION; PATHOLOGY; TUMOR CELL LINE;

AFLATOXIN B1; ANIMALS; CARCINOGENS; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; CHINA; DNA MUTATIONAL ANALYSIS; HEPATITIS B SURFACE ANTIGENS; HUMANS; LIVER NEOPLASMS; MICE; MUTATION;

EID: 85028748836     PISSN: 10889051     EISSN: 15495469     Source Type: Journal    
DOI: 10.1101/gr.220038.116     Document Type: Article

References (49)

1. Alexandrov LB, Stratton MR. 2014. Mutational signatures: the patterns of somatic mutations hidden in cancer genomes. Curr Opin Genet Dev 24: 52-60.
2. Alexandrov LB, Nik-Zainal S, Wedge DC, Aparicio SA, Behjati S, Biankin AV, Bignell GR, Bolli N, Borg A, Borresen-Dale AL, et al. 2013. Signatures of mutational processes in human cancer. Nature 500: 415-421.
3. Ambolet-Camoit A, Ottolenghi C, Leblanc A, Kim MJ, Letourneur F, Jacques S, Cagnard N, Guguen-Guillouzo C, Barouki R, Aggerbeck M. 2015. Two persistent organic pollutants which act through different xenosensors (α-endosulfan and 2, 3, 7, 8 tetrachlorodibenzo-p-dioxin) interact in a mixture and downregulate multiple genes involved in human hepato-cyte lipid and glucose. Biochimie 116: 79-91.
4. Bailey EA, Iyer RS, Stone MP, Harris TM, Essigmann JM. 1996. Mutational properties of the primary aflatoxin B1-DNA adduct. Proc Natl Acad Sci 93: 1535-1539.
5. Blokzijl F, de Ligt J, Jager M, Sasselli V, Roerink S, Sasaki N, Huch M, Boymans S, Kuijk E, Prins P, et al. 2016. Tissue-specific mutation accu-mulation in human adult stem cells during life. Nature 538: 260-264.
6. Chawanthayatham S, Valentine CC, Fedeles BI, Fox EJ, Loeb LA, Levine SS, Slocum SL, Wogan GN, Croy RG, Essigmann JM. 2017. Mutational spectra of aflatoxin B1 in vivo establish biomarkers of exposure for human hepatocellular carcinoma. Proc Natl Acad Sci 114: E3101-E3109.
7. Chisari F, Pinkert C, Milich D, Filippi P, McLachlan A, Palmiter R, Brinster R. 1985. A transgenic mouse model of the chronic hepatitis B surface antigen carrier state. Science 230: 1157-1160.
8. Chittmittrapap S, Chieochansin T, Chaiteerakij R, Treeprasertsuk S, Klaikaew N, Tangkijvanich P, Komolmit P, Poovorawan Y. 2013. Prevalence of aflatoxin induced p53 mutation at codon 249 (R249s) in hepatocellular carcinoma patients with and without hepatitis B surface antigen (HBsAg). Asian Pac J Cancer Prev 14: 7675-7679.
9. Conaway JW, Conaway RC. 1999. Transcription elongation and human disease. Annu Rev Biochem 68: 301-319.
10. 7-guanine in human urine by high-performance liquid chromatography and isotope dilution tandem mass spectrometry. Chem Res Toxicol 19: 1191-1195.
11. Foster P, Eisenstadt E, Miller J.1983. Base substitution mutations induced by metabolically activated aflatoxin B1. Proc Natl Acad Sci 80: 2695-2698.
12. Fousteri M, Mullenders LH. 2008. Transcription-coupled nucleotide excision repair in mammalian cells: molecular mechanisms and biological effects. Cell Res 18: 73-84.
13. Fujimoto A, Furuta M, Totoki Y, Tsunoda T, Kato M, Shiraishi Y, Tanaka H, Taniguchi H, Kawakami Y, Ueno M, et al. 2016. Whole-genome muta-tional landscape and characterization of noncoding and structural mutations in liver cancer. Nat Genet 48: 500-509.
14. Gerets HH, Tilmant K, Gerin B, Chanteux H, Depelchin BO, Dhalluin S, Atienzar FA. 2012. Characterization of primary human hepatocytes, HepG2 cells, and HepaRG cells at the mRNA level and CYP activity in response to inducers and their predictivity for the detection of human hepatotoxins. Cell Biol Toxicol 28: 69-87.
15. Groopman JD, Donahue PR, Zhu J, Chen J, Wogan GN. 1985. Aflatoxin metabolism in humans: detection of metabolites and nucleic acid adducts in urine by affinity chromatography. Proc Natl Acad Sci 82: 6492-6496.
16. Guengerich FP, Johnson WW, Shimada T, Ueng Y-F, Yamazaki H, Langouët S. 1998. Activation and detoxication of aflatoxin B 1. Mutat Res 402: 121-128.
17. Hart SN, Li Y, Nakamoto K, Subileau EA, Steen D, Zhong XB. 2010. A comparison of whole genome gene expression profiles of HepaRG cells and HepG2 cells to primary human hepatocytes and human liver tissues. Drug Metab Dispos 38: 988-994.
18. Helleday T, Eshtad S, Nik-Zainal S. 2014.Mechanisms underlying mutation-al signatures in human cancers. Nat Rev Genet 15: 585-598.
19. Hoang ML, Chen CH, Sidorenko VS, He J, Dickman KG, Yun BH, Moriya M, Niknafs N, Douville C, Karchin R, et al. 2013. Mutational signature of aristolochic acid exposure as revealed by whole-exome sequencing. Sci Transl Med 5: 197ra102.
20. Hollstein M, Sidransky D, Vogelstein B, Harris CC. 1991. p53 mutations in human cancers. Science 253: 49-53.
21. Hollstein M, Alexandrov LB, Wild CP, Ardin M, Zavadil J. 2016. Base changes in tumour DNA have the power to reveal the causes and evolution of cancer. Oncogene 36: 158-167.
22. Hu J, Adar S, Selby CP, Lieb JD, Sancar A. 2015. Genome-wide analysis ofhu-man global and transcription-coupled excision repair of UV damage at single-nucleotide resolution. Genes Dev 29: 948-960.
23. IARC Working Group on the Evaluation of Carcinogenic Risks to Humans. 2012. A review of human carcinogens. Part F:Chemical agents and related occupations. International Agency for Research on Cancer, Lyon, France.
24. Kensler TW, Qian GS, Chen JG, Groopman JD. 2003. Translational strategies for cancer prevention in liver. Nat Rev Cancer 3: 321-329.
25. Kensler TW, Roebuck BD, Wogan GN, Groopman JD. 2011. Aflatoxin: a 50-year odyssey of mechanistic and translational toxicology. Toxicological Sciences 120: S28-S48.
26. Kew MC. 2013. Synergistic interaction between aflatoxin and hepatitis B virus in hepatocarcinogenesis. In Aflatoxins-recent advances and future prospects (ed. Razzaghi-Abyaneh M). InTech Open Access Publisher, Rijeka, Croatia.
27. Lee DD, Seung HS. 1999. Learning the parts of objects by non-negative matrix factorization. Nature 401: 788-791.
28. Liu F, Ren C, Li H, Zhou P, Bo X, Shu W.2015. De novo identification of replication-timing domains in the human genome by deep learning. Bioinformatics 32: 641-649.
29. Meier B, Cooke SL, Weiss J, Bailly AP, Alexandrov LB, Marshall J, Raine K, Maddison M, Anderson E, Stratton MR, et al. 2014. C. Elegans whole-genome sequencing reveals mutational signatures related to carcinogens and DNA repair deficiency. Genome Res 24: 1624-1636.
30. Ming L, Thorgeirsson SS, Gail MH, Lu P, Harris CC, Wang N, Shao Y, Wu Z, Liu G, Wang X, et al. 2002. Dominant role ofhepatitis Bvirus and cofac-tor role of aflatoxin in hepatocarcinogenesis in Qidong, China. Hepatology 36: 1214-1220.
31. Montesano R, Hainaut P, Wild C. 1997. Hepatocellular carcinoma: from gene to public health. J Natl Cancer Inst 89: 1844-1851.
32. Nik-Zainal S, Kucab JE, Morganella S, Glodzik D, Alexandrov LB, Arlt VM, Weninger A, Hollstein M, Stratton MR, Phillips DH. 2015. The genome as a record of environmental exposure. Mutagenesis 30: 763-770.
33. Olivier M, Weninger A, Ardin M, Huskova H, Castells X, Vallee MP, McKay J, Nedelko T, Muehlbauer KR, Marusawa H, et al. 2014. Modelling muta-tional landscapes of human cancers in vitro. Sci Rep 4: 4482.
34. Pascual-Montano A, Carazo JM, Kochi K, Lehmann D, Pascual-Marqui RD. 2006. Nonsmooth nonnegative matrix factorization (nsNMF). IEEE Trans Pattern Anal Mach Intell 28: 403-415.
35. Poon SL, Pang ST, McPherson JR, Yu W, Huang KK, Guan P, Weng WH, Siew EY, Liu Y, Heng HL, et al. 2013. Genome-wide mutational signatures of aristolochic acid and its application as a screening tool. Sci Transl Med 5: 197ra101.
36. Poon SL, McPherson JR, Tan P, Teh BT, Rozen SG. 2014. Mutation signatures of carcinogen exposure: genome-wide detection and new opportunities for cancer prevention. Genome Med 6: 24.
37. Poon SL, Huang MN, Yang C, McPherson JR, Yu W, Heng HL, Gan A, Myint SS, Siew EY, Ler LD, et al. 2015. Mutation signatures implicate aristolo-chic acid in bladder cancer development. Genome Med 7: 38.
38. R Core Team. 2017. R: a language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. http://www.R-project.org/.
39. Schulze K, Imbeaud S, Letouze E, Alexandrov LB, Calderaro J, Rebouissou S, Couchy G, Meiller C, Shinde J, Soysouvanh F, et al. 2015. Exome sequencing of hepatocellular carcinomas identifies new mutational signatures and potential therapeutic targets. Nat Genet 47: 505-511.
40. Severson PL, Vrba L, Stampfer MR, Futscher BW. 2014. Exome-wide mutation profile in benzo[a]pyrene-derived post-stasis and immortal human mammary epithelial cells. Mutat Res Genet Toxicol Environ Mutagen 775-776: 48-54.
41. Shen Y, Yue F, McCleary DF, Ye Z, Edsall L, Kuan S, Wagner U, Dixon J, Lee L, Lobanenkov VV, et al. 2012. A map of the cis-regulatory sequences in the mouse genome. Nature 488: 116-120.
42. Sun G, Wang S, Hu X, Su J, Zhang Y, Xie Y, Zhang H, Tang L, Wang J-S. 2011. Co-contamination of aflatoxin B1 and fumonisin B1 in food and human dietary exposure in three areas of China. Food Addit Contam Part A Chem Anal Control Expo Risk Assess 28: 461-470.
43. Sung WK, Zheng H, Li S, Chen R, Liu X, Li Y, Lee NP, Lee WH, Ariyaratne PN, Tennakoon C, et al. 2012. Genome-wide survey of re-current HBV integration in hepatocellular carcinoma. Nat Genet 44: 765-769.
44. Szymanska K, Chen JG, Cui Y, Gong YY, Turner PC, Villar S, Wild CP, Parkin DM, Hainaut P. 2009. TP53 R249S mutations, exposuretoaflatoxin, and occurrence of hepatocellular carcinoma in a cohort of chronic hepatitis B virus carriers from Qidong, China. Cancer Epidemiol Biomarkers Prev 18: 1638-1643.
45. Teoh WW, Xie M, Vijayaraghavan A, Yaligar J, Tong WM, Goh LK, Sabapathy K. 2015. Molecular characterization of hepatocarcinogenesis using mouse models. Dis Model Mech 8: 743-753.
46. Wang J, Liu XM. 2007. Contamination of aflatoxins in different kinds of foods in China. Biomed Environ Sci 20: 483-487.
47. Wild C, Garner R, Montesano R, Tursi F. 1986. Aflatoxin B1 binding to plasma albumin and liver DNA upon chronic administration to rats. Carcinogenesis 7: 853-858.
48. Zamborszky J, Szikriszt B, Gervai JZ, Pipek O, Poti A, Krzystanek M, Ribli D, Szalai-Gindl JM, Csabai I, Szallasi Z, et al. 2016. Loss of BRCA1 or BRCA2 markedly increases the rate of base substitution mutagenesis and has distinct effects on genomic deletions. Oncogene 36: 746-755.
49. Zhang W, He H, Zang M, Wu Q, Zhao H, Lu L-l, Ma P, Zheng H, Wang N, Zhang Y. 2017. Genetic features of aflatoxin-associated hepatocellular carcinomas. Gastroenterology 153: 249-262.e2.